SCHEMBL17071998

SCHEMBL17071998

COC(=O)c1ccc(N)c(Cl)c1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.61
ALDH1A1 P00352 5/20 0.53
HSD17B10 Q99714 3/20 0.53
CFTR P13569 2/20 0.53
KDM4E B2RXH2 7/20 0.53
GAA P10253 6/20 0.53
GLA P06280 3/20 0.53
MAPT P10636 2/20 0.53
HPGD P15428 2/20 0.53
CASP1 P29466 1/20 0.53
CASP7 P55210 1/20 0.53
ATM Q13315 1/20 0.53
TSHR P16473 3/20 0.50
ALOX15 P16050 1/20 0.50
NQO2 P16083 3/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43
PDK2 Q15119 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL523584 0.88 ABL1 (0.57) ABL1ALDH1A1HSD17B10CFTRKDM4E
SCHEMBL31280031 0.87 ABL1 (0.59) ABL1ALDH1A1HSD17B10CFTRKDM4E
SCHEMBL22905002 0.87 ABL1 (0.59) ABL1ALDH1A1HSD17B10CFTRKDM4E
SCHEMBL3133978 0.85 ABL1 (0.57) ABL1ALDH1A1HSD17B10CFTRKDM4E
SCHEMBL1578948 0.85 ABL1 (0.57) ABL1ALDH1A1HSD17B10CFTRKDM4E
SCHEMBL3666380 0.85 ABL1 (0.57) ABL1ALDH1A1HSD17B10CFTRKDM4E
SCHEMBL23537740 0.84 ABL1 (0.56) ABL1ALDH1A1HSD17B10CFTRKDM4E
SCHEMBL10514582 0.84 ABL1 (0.56) ABL1ALDH1A1HSD17B10CFTRKDM4E
SCHEMBL13715480 0.84 ABL1 (0.56) ABL1ALDH1A1HSD17B10CFTRKDM4E
SCHEMBL903478 0.84 ABL1 (0.56) ABL1ALDH1A1HSD17B10CFTRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200262850-A1 SUBSTITUTED ASYMMETRIC UREAS AS MODULATORS OF GHRELIN RECEPTOR ACTIVITY HELSINN HEALTHCARE SA (CH) 2020-08-20 US disclosed
EP-3114118-B1 P-SUBSTITUTED ASYMMETRIC UREAS AND MEDICAL USES THEREOF HELSINN HEALTHCARE SA (CH) 2020-07-22 EP disclosed
US-10577384-B2 Substituted asymmetric ureas as modulators of ghrelin receptor activity HELSINN HEALTHCARE SA (CH) 2020-03-03 US disclosed
US-9926337-B2 Substituted asymmetric ureas as modulators of ghrelin receptor activity HELSINN HEALTHCARE SA (CH) 2018-03-27 US disclosed
US-20170145038-A1 SUBSTITUTED ASYMMETRIC UREAS AND MEDICAL USES THEREOF HELSINN HEALTHCARE SA (CH) 2017-05-25 US disclosed
US-9546157-B2 Asymmetric piperidinyl-substituted ureas as medicines HELSINN HEALTHCARE SA (CH) 2017-01-17 US disclosed
WO-2015134839-A1 P-SUBSTITUTED ASYMMETRIC UREAS AND MEDICAL USES THEREOF HELSINN HEALTHCARE SA (CH) 2015-09-11 WO disclosed
US-20150252021-A1 p-Substituted Asymmetric Ureas and Medical Uses Thereof HELSINN HEALTHCARE SA (CH) 2015-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10577384-B2 Substituted asymmetric ureas as modulators of ghrelin receptor activity GHSR, GIPR, UTS2R ABL1 2984/4885ALDH1A1 3283/4885HSD17B10 2204/4885
US-20150252021-A1 p-Substituted Asymmetric Ureas and Medical Uses Thereof UTS2R, GIPR, GPR119 ABL1 2822/4885ALDH1A1 2353/4885HSD17B10 2601/4885
US-20200262850-A1 SUBSTITUTED ASYMMETRIC UREAS AS MODULATORS OF GHRELIN RECEPTOR ACTIVITY GHSR, GIPR, UTS2R ABL1 2984/4885ALDH1A1 3283/4885HSD17B10 2204/4885
US-20170145038-A1 SUBSTITUTED ASYMMETRIC UREAS AND MEDICAL USES THEREOF UTS2R, GHSR, GPR119 ABL1 2170/4885ALDH1A1 1977/4885HSD17B10 1849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.